Stay updated on Pembrolizumab and Olaparib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference5%
- Check39 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check53 days agoChange DetectedThe website has been updated to version 2.14.1 on January 16, 2025, following the removal of version 2.14.0 on November 19, 2024.SummaryDifference1%
- Check60 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference1.0%
- Check89 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.3%
Stay in the know with updates to Pembrolizumab and Olaparib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.